Research and science related to a minor improvement in hairgrowth caused by the use of verteporfin, as well as potential treatments such as Minoxidil, Finasteride, and RU58841.
PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.
Dutasteride is effective for many in reducing hair loss and promoting regrowth, often with fewer side effects than finasteride. Combining it with minoxidil is commonly seen as a successful strategy, though results may take several months.
Dutasteride is more effective than finasteride for some in stopping hair loss and promoting regrowth, with fewer side effects. Oral minoxidil is also used for regrowth, but there are safety concerns, especially for younger users.
A user is trying 2-deoxy-D-ribose with distilled water for hairgrowth, observing new hair and skin pigmentation changes. Others compare it to Minoxidil, expressing interest and caution about its effectiveness and safety.
Whether topical caffeine can be as effective for hairgrowth as minoxidil and finasteride, with various replies discussing the efficacy of these treatments and criticism of Dr. Huberman's research methods.
Peppermint oil at 3% was found to improve hairgrowth more effectively than Minoxidil. The user is also using a topical caffeine hairgrowth oil and making their own peppermint solution to combat hair thinning.
A female with suspected hair loss is considering using vitamins, a dermaroller, and essential oils to stimulate hairgrowth. Advice includes choosing a dermaroller with needles, preferably stainless steel.
The user is considering alternatives to topical minoxidil for hairgrowth due to concerns about future cat ownership, mentioning stemoxydine and redensyl as possibilities. They currently use topical regaine foam and oral finasteride.
Combining microneedling with Low Level Laser Therapy (LLLT) for hairgrowth, with discussions on device legitimacy and effectiveness. Alternatives like PEMF and the use of oral and topical treatments such as dutasteride, minoxidil, and finasteride are also considered.
The user added melatonin to their 5% minoxidil solution for hairgrowth, using a concentration of 0.0033%, which equates to roughly 2mg for a 60ml bottle. They later reported no significant difference and planned to continue the treatment for a few more months before potentially stopping to observe any changes in shedding.
The conversation discusses the potential positive effects of melatonin on hairgrowth. The original poster plans to try both oral and topical melatonin and is seeking recommendations for a good source.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.
Collagen peptides are recommended for hair and skin benefits, with users noting improvements in hair and skin health. However, evidence on their effectiveness for hairgrowth is inconclusive.
Low-Level Laser Therapy (LLLT) is seen as a safe and effective method for maintaining hair and promoting regrowth in androgenetic alopecia (AGA) and male pattern baldness (MPB), with devices like the HairMax LaserComb® and iRestore helmet being popular. Some users and professionals are skeptical about its long-term effectiveness and cost.
Rob English, known for promoting scalp massages for hair regrowth, now sells his own brand of finasteride and minoxidil. Opinions are mixed, with some calling him a charlatan and others acknowledging his shift towards scientifically-backed treatments.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.
Travoprost may be more effective than minoxidil for hairgrowth and can be used alongside it, but its effectiveness is debated due to inconsistent dosing results. Travoprost is expensive and not widely used, with alternatives like latanoprost and bimatoprost being more accessible.
Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hairgrowth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.
Piroctone Olamine at 1% is recommended for reducing scalp inflammation and encouraging hairgrowth. The user seeks recommendations for UK shampoos/conditioners containing this ingredient.
A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.
Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.
SCUBE3, a protein linked to hairgrowth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hairgrowth therapy.
Switching from finasteride to dutasteride led to hair density loss, prompting consideration of returning to finasteride. Consistency with dutasteride and adding RU58841 did not prevent the loss, and users suggest giving dutasteride more time or consulting a dermatologist.
Switching from topical to oral minoxidil can cause initial hair shedding but may lead to thicker hairgrowth. Many users combine it with finasteride, experiencing varying side effects.
A South Korean company, Therazyne, has developed a promisinghair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.
The conversation discusses skepticism about a user's hair restoration progress, with accusations of the post being fake and promoting an AI app. Treatments mentioned include dutasteride and oral minoxidil, with some users discussing side effects and safety of minoxidil.
The conversation discusses using a TCA 35% chemical peel on the scalp to potentially improve hairgrowth by addressing fibrosis and enhancing the effectiveness of topical treatments. The user also mentions trying microneedling and other methods like topical metformin and dutasteride for hair regrowth.
Hmi115, a prolactin receptor blocker, showed promise for hairgrowth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.